Related Experiment Video

Updated: Aug 30, 2026

Assessing Endothelial Vasodilator Function with the Endo-PAT 2000
07:46

Assessing Endothelial Vasodilator Function with the Endo-PAT 2000

Published on: October 15, 2010

Elevation of plasmatic endothelin in patients with heart failure

Arturo Galindo-Fraga1, Oscar Arrieta, Lilia Castillo-Martínez

  • 1Departamento de Enfermedades Infecciosas, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, DF, Mexico.

Archives of Medical Research
|November 7, 2003
PubMed

Insights

Elevated endothelin 1 levels indicate greater heart failure severity, independent of other markers. This suggests endothelin 1 is a key factor in heart failure and a potential therapeutic target.

Area of Science:

  • Cardiology
  • Endocrinology
  • Biomedical Science

Background:

  • Endothelin 1 (ET-1) is a potent vasoconstrictive and mitogenic factor.
  • ET-1 levels are elevated in chronic heart failure patients.
  • Disease-activated neurohumoral factors may influence ET-1 production.

Purpose of the Study:

  • Correlate serum endothelin levels with clinical and echocardiographic heart failure markers.
  • Determine endothelin's role as an independent marker of heart failure severity.
  • Investigate endothelin's involvement in heart failure pathophysiology.

Main Methods:

  • Radioimmunoassay (RIA) used to measure serum endothelin 1 levels.
  • Included patients with congestive heart failure and available echocardiographic and biochemical data.
  • Statistical analysis to correlate endothelin with severity, echocardiographic parameters, and confounding factors.

Main Results:

  • Higher endothelin levels observed in symptomatic heart failure patients with longer disease duration.
  • Endothelin levels were not correlated with troponin T, tumor necrosis factor, or atrial natriuretic peptide.
  • No significant differences in endothelin levels were found based on the etiology of heart failure.

Conclusions:

  • Endothelin 1 plays a significant, independent role in heart failure pathophysiology.
  • Endothelin 1 may serve as a valuable severity marker for heart failure.
  • Endothelin 1 represents an attractive therapeutic target for heart failure management.
Abstract

More Related Videos

Induction and Phenotyping of Acute Right Heart Failure in a Large Animal Model of Chronic Thromboembolic Pulmonary Hypertension07:41

Induction and Phenotyping of Acute Right Heart Failure in a Large Animal Model of Chronic Thromboembolic Pulmonary Hypertension

Published on: March 17, 2022

Related Concept Videos

Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
Heart Failure III: Clinical Manifestations01:26

Heart Failure III: Clinical Manifestations

Heart failure (HF) manifests primarily as dyspnea, fatigue, and fluid retention, resulting in peripheral and pulmonary edema. Symptoms may vary depending on which ventricle is more affected, left or right.Left-Sided Heart FailureAlso known as left ventricular failure, this condition results from the left ventricle's inability to fill or eject sufficient blood into the systemic circulation. It leads to pulmonary congestion, which occurs when the left ventricle fails to eject blood effectively...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...